Fig. 1: Translational research on the NA-PHER2 trial. | Nature Communications

Fig. 1: Translational research on the NA-PHER2 trial.

From: Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies

Fig. 1

A Schematic representation of the NA-PHER2 trial and associated serial sample collection. The number of samples for which RNA sequencing (RNA-seq), Ki67 quantification and TIL scoring were performed are indicated for each timepoint. B Annotated heatmap of 904 most expressed and variant genes. sTILs = stromal tumour infiltrating lymphocytes; iTILs = intra-tumoral infiltrating lymphocytes; pCR = pathologic complete response; RD = residual disease. Source data are provided as a Source Data file.

Back to article page